TECL vs XBI
Direxion Daily Technology Bull 3X ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.87% for TECL.
- • TECL pays a higher dividend yield (5.71%).
Side-by-side metrics
| Metric | TECL | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.87% | 0.35% |
Dividend yield Trailing 12-month yield. | 5.71% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $4.77B | $8.30B |
YTD return | 49.99% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 4.36 | 1.09 |
P/E ratio | 41.79 | — |
Last price | $174.84 | $133.66 |
Inception | — | — |
Issuer | Direxion | State Street |
TECL top holdings
| NVDA | NVIDIA Corp | 10.05% |
| AAPL | Apple Inc | 8.25% |
| MSFT | Microsoft Corp | 6.27% |
| AVGO | Broadcom Inc | 4.10% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About TECL
TECL (Direxion Daily Technology Bull 3X ETF) is 3x daily performance of the S&P tech sector. Managed by Direxion, the fund carries $4.8B in assets under management, an expense ratio of 0.87%, a dividend yield of 5.71%. Its largest holding is NVIDIA Corp (NVDA), which represents 10.0% of the portfolio. Technology is the fund's largest sector exposure at 99.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.